Article thumbnail

Targeted treatment of chronic myeloid leukemia: role of imatinib

By Ila Tamascar and Jeyanthi Ramanarayanan

Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by clonal expansion of pleuripotent hematopoetic stem cells. The incidence of CML is 1 to 2 cases per 100,000 people per year; in the Western Hemisphere, CML accounts for 15% of leukemias in adults. Discovery of the specific karyotypic abnormality of the Philadelphia (Ph) chromosome in the pathogenesis of CML has led to a better understanding of the disease and hence to an advancement of targeted therapeutics. Availability of imatinib as an accepted targeted therapy in newly diagnosed patients has changed the treatment paradigm in CML. The majority of CML patients in chronic phase achieve excellent and durable responses with standard-dose imatinib. Mechanisms of primary and secondary resistance to imatinib in CML have been extensively studied and newer tyrosine kinase inhibitors are now being evaluated for clinical use. It is important that at any time the CML treatment and response remain optimal and thus patients on imatinib require continuous monitoring for early detection of resistance. This review will discuss the treatment and guidelines for monitoring CML patients in the imatinib era

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2886320
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. A minute chromosome in human granulocytic leukemia.
  2. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identifi ed by quinacrine fl uorescence and Giemsa staining.
  3. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosomepositive chronic myelogenous leukemia in chronic phase.
  4. (1999). Chronic myelogenous leukemia. biology and therapy. Ann Int Med.
  5. (2009). Chronic myelogenous leukemia. National Comprehensive Care Network Practice guidelines in oncology.
  6. Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib. Leuk Lymphoma.
  7. Dasatinib in imatinibresistant Philadelphia chromosome-positive leukemias.
  8. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia.
  9. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.
  10. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia.
  11. (1996). Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med.
  12. (2006). Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
  13. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
  14. Four years of follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials [abstract].
  15. Frequency and clinical signifi cance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate.
  16. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia.
  17. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
  18. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
  19. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
  20. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
  21. Imatinib mesylate – a new oral targeted therapy.
  22. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.
  23. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: Results and prognostic factors for response and progressionfree survival in 150 patients.
  24. (1990). Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR-ABL.
  25. (1990). Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.
  26. Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.
  27. (1999). Medical Progress. Chronic myeloid leukemia.
  28. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods.
  29. Most CML patients who have a sub optimal response to imatinib have low OCT-1 activity; higher doses of imatinib may overcome the negative impact of low OCT-1 activity.
  30. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML.
  31. OCT-1 mediated infl ux is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN 107): reduced OCT 1 activity is the cause of low in vitro sensitivity to imatinib.
  32. on behalf of the IRIS study group. Benefi cial effects of cytogenetic and molecular response on long term outcome in patients with newly diagnosed chronic myeloid leukemia
  33. Overriding imatinib resistance with a novel ABL kinase inhibitor.
  34. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia.
  35. (2007). Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett.
  36. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia.